OraSure expects Q3 revenue of $29.5M-$32.5M while delaying InteliQuick CT/NG FDA clearance beyond 2026 (NASDAQ:OSUR)
· seekingalpha.com
OraSure (OSUR) Q2 2026 earnings call highlights: revenue/gross margin gains, FDA wins, CT/NG setback, and 2026–27 outlook.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...